Theator Extends Series A Funding with Additional $24M for a Total of $39.5M -PALO ALTO, Calif., July 22, 2022 /PRNewswire/ — Theator, the creator of Surgical Intelligence, announced today that it has raised $24M in an extension of its Series A funding round. This extension follows an initial $15.5M Series A round announced in February 2021, bringing the round total to $39.5M. The extended funding round was once again led by Insight Partners with support from existing investors including Blumberg Capital, Mayo Clinic, NFX, StageOne Ventures, iAngels, and former Netflix Chief Product Officer Neil Hunt. In addition, new growth investors including iCON and TripActions’ CEO and Co-founder Ariel Cohen joined the round.
IQM Raises €128M in Series A2 Funding – IQM Quantum Computers (IQM), an Espoo, Finland-based builder of superconducting quantum computers, raised €128m ($128m) in Series A2 funding.
Zededa Closes $26M Series B Funding Round –
Zededa, a San Jose, Calif.-based leader in edge orchestration, closed $26m Series B funding.
Backers included Coast Range Capital, Lux Capital, Energize Ventures, Almaz Capital, Porsche Ventures, Chevron Technology Ventures, Juniper Networks, Rockwell Automation, Samsung Next and EDF North America Ventures.
Quantifi Photonics adds $15 million in Series C funding – New Zealand-based photonic test and measurement company Quantifi Photonics has announced the receipt of $15 million in a fully subscribed Series C capital round. Intel Capital, the venture capital arm of Intel Corp., led the round alongside the rest of Quantifi Photonics’ existing investors.
Sports streaming specialist Phenix scores $16.7M in new funding – Phenix, a technology platform specializing in synchronized video streams and low latency, closed a $16.7 million Series B funding round with investors including Verizon.
Ropes & Gray Represents CAMP4 Therapeutics in $100 Million Series B Financing – Ropes & Gray represented CAMP4 Therapeutics in a $100 million Series B financing. CAMP4 is pioneering a novel class of RNA-based therapies designed to dial up the output of genes to treat genetic diseases. The company will use the funds to advance its lead programs into the clinic, with an initial focus on a severe form of epilepsy and life-threatening liver diseases.